FDA Approves First-Ever Gene Therapy for Genetic Hearing Loss

The FDA has granted approval for Otarmeni, the first-ever gene therapy designed to treat genetic hearing loss caused by the OTOF gene mutation. This breakthrough offers hope for both pediatric and adult patients suffering from irreversible deafness, marking a significant shift in medical capabilities. The approval represents a major victory for medical science and underscores the potential for gene therapies to restore quality of life for millions.